New research indicates that individuals who stop using new weight-loss injections like semaglutide or tirzepatide may regain shed pounds far faster than those who stop traditional lifestyle plans.
Findings released in a prominent medical journal demonstrates that while overweight individuals often shed substantial amounts of their body weight while on the medication, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing these drugs need to be aware of the potential of rapid weight regain when the therapy ends," warns researcher Dr. Susan Jebb.
Such speed of regain implies a reversion to pre-treatment mass within about a year and a half.
Weighing Approaches
The study, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
Researchers note that individuals who shed pounds through lifestyle changes alone usually see a more gradual weight regain—perhaps 0.1 kg a month—after stopping.
Understanding the Rapid Regain
Experts suggest the mechanism of the jabs accounts for the heightened regain.
GLP-1 drugs mimic a natural hormone called GLP-1, which helps regulate appetite.
"Artificially providing GLP-1 concentrations several times higher than normal may cause the body to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' leads to appetite is uncontrolled, making excessive eating far more likely."
A Chronic Issue?
The NHS suggest the jabs for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Professionals contend that, given the likelihood of weight regain, the treatment should be considered long-term.
This view is echoed by pharmaceutical companies, who state that the results "highlight the persistent character of excess weight," akin to managing conditions like diabetes.
User Accounts
Users who have discontinued the jabs explain a intense resurgence of cravings.
"I experienced a switch activating and you become extremely hungry," recalled a patient.
This challenge is worsened if users have not established lasting lifestyle or habit changes during therapy.
Widespread Use
Recent estimates show that millions of people in the UK have tried weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is greater among females than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while these medications are potent tools for weight loss, they are not a magic cure and long-term success likely depends on combined lifestyle support.
